DMP1 Genotype

If you have a family history of unexplained bone pain, leg bowing, short stature, or unusually fragile teeth that have appeared across generations, this test can tell you whether you carry the specific gene change behind a rare inherited bone disease. Knowing your genotype early lets you and your relatives act before symptoms become irreversible, rather than waiting for years of confusing specialist visits.

This is a one-time genetic test. Your result will not change throughout your life, but how you and your family use it will shape decisions about bone health, dental care, and screening for years to come.

What This Gene Does

DMP1 (dentin matrix protein 1) is a gene that tells your body how to build a protein found in bone and tooth tissue. The protein is made mostly by the cells buried deep inside your bones (osteocytes) and the cells that build teeth from the inside out (odontoblasts), with additional expression in bone-forming osteoblasts. Its job is to organize the mineral crystals that make bone and dentin hard.

DMP1 also helps regulate phosphate, a mineral your body needs to harden bones. It does this by keeping a hormone called FGF23 (fibroblast growth factor 23) in check. FGF23 tells your kidneys to dump phosphate into the urine. When DMP1 is missing or broken, FGF23 climbs, the kidneys throw away too much phosphate, and there is not enough left in the blood to mineralize bone properly.

The Disease This Test Detects

When both copies of the DMP1 gene carry a loss-of-function mutation, the result is autosomal recessive hypophosphatemic rickets type 1, often shortened to ARHR1. People with this condition have low phosphate in the blood from wasted phosphate in the urine, inappropriately high or normal FGF23, and bones that fail to mineralize correctly.

The clinical picture includes short stature, bowed legs, painful enthesopathy (calcium buildup where tendons attach to bone), thickening of the skull, and a paradoxical mix of dense and undermineralized bone. Teeth often have enlarged pulp chambers, abscesses, and may be lost early. Hearing problems have also been reported in some patients.

Where in the gene the mutation lands matters. Mutations affecting the C-terminal portion of the DMP1 protein tend to cause more severe short stature and lower phosphate levels than mutations limited to the N-terminal portion.

How Inheritance Works

ARHR1 is autosomal recessive. You need two altered copies of the gene, one from each biological parent, to develop the disease. People with only one altered copy are called carriers and typically have no symptoms, although a few studies have noted subtle bone or dental findings in carriers.

If both of your biological parents are carriers, each of their children has a one in four chance of inheriting two altered copies and developing the disease, a two in four chance of being a carrier, and a one in four chance of inheriting two unaffected copies. Consanguinity in a family raises the odds that both parents carry the same rare variant.

Vascular and Kidney Implications Beyond the Bone

Research has connected the DMP1 protein, not just the gene mutations, to vascular health in people with kidney disease. In a study of patients on peritoneal dialysis, those with lower circulating DMP1 protein levels had more calcium buildup in their blood vessels and were more likely to suffer a major cardiovascular event such as heart attack or stroke. This evidence applies to the DMP1 protein measured in blood, not to your genotype directly, but it shows why this gene matters for more than just bones.

Reading Your Result

Your result will fall into one of three broad categories. Two altered copies (homozygous or compound heterozygous loss-of-function variants) indicates you have the genetic basis for ARHR1. One altered copy (heterozygous) indicates you are a carrier; you are unlikely to develop the full disease but can pass the variant to your children. No detected variants means none of the variants the panel checks for were found, which lowers your likelihood of ARHR1 but does not completely rule it out, because some rare variants may sit outside the panel's reach.

When Results Can Be Misleading

A few specific situations can make a DMP1 genotype harder to interpret, and they are different from the confounders that affect a blood chemistry test.

• Variant panel coverage: the test only detects the specific changes it is designed to look for, so a negative result does not rule out every possible rare variant in the gene. If your clinical picture strongly suggests ARHR1, additional sequencing of the entire gene may be needed.
• Variants of uncertain significance: sometimes the lab finds a change in the gene that has not been seen often enough to know whether it causes disease. This is not a definitive answer in either direction and may need expert review.
• Ancestry-specific variants: some DMP1 changes are more common in certain populations. The clinical meaning of a variant can depend on whether it has been studied in people with similar ancestry.
• Confusion with related conditions: ARHR1 can look like X-linked hypophosphatemia, ARHR2 (caused by ENPP1), or FGF23-driven disease from FAM20C mutations. A negative DMP1 result does not rule out these other genetic causes of low-phosphate bone disease.

One-Time Result, Lifelong Use

Your DMP1 genotype does not change, so this test does not need to be repeated. The exception is if the result is uncertain or unexpected; in that case, a confirmatory test using a different sequencing method may be warranted.

The value of testing once comes from the decisions it shapes over many years. People who learn they carry two altered copies, or who already have a clinical picture suggesting ARHR1, need ongoing monitoring of phosphate, alkaline phosphatase, calcium, vitamin D, FGF23, parathyroid hormone, and kidney function. Bone density and dental imaging should be tracked over time. The companion lab tests are where serial monitoring happens, not the genetic test itself.

What to Do With an Out-of-Pattern Result

If your test identifies two altered DMP1 copies, the next steps usually include a confirmatory genetic test through Sanger sequencing if the original method was a SNP chip, and a referral to a metabolic bone specialist or endocrinologist familiar with hypophosphatemic rickets. Burosumab, an antibody that blocks FGF23, has been used off-label in adults with ARHR1 based on published case reports, where it helped normalize phosphate levels, heal pseudofractures, and reduce bone pain. It is not FDA-approved for ARHR1, only for X-linked hypophosphatemia and tumor-induced osteomalacia. A dentist who understands the dental features of this disease should also be on the team.

If you are identified as a carrier, the most important step is conversation with biological family members. Siblings have a fifty-fifty chance of also being carriers. Your future children's risk depends on whether your reproductive partner is also a carrier. A genetic counselor can walk you through the math and help your relatives decide whether to test.

If no variants are detected but you have unexplained bone or dental findings, the next step is broader genetic testing, because related genes such as PHEX, FGF23, ENPP1, and FAM20C can produce similar pictures, and standard DMP1 panels will not catch them.